Literature DB >> 29982318

Sepsis and Risk of Cancer Among Elderly Adults in the United States.

Zhiwei Liu1, Parag Mahale1, Eric A Engels1.   

Abstract

BACKGROUND: Sepsis is an important cause of mortality among older adults in the United States. The association between sepsis and subsequent risk of cancer is poorly understood.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, we conducted a case-control study in US adults. We included 1801156 cases with a first cancer diagnosis in SEER during 1992-2013 (ages 66-115 years) and 200000 cancer-free controls from a 5% random sample of Medicare beneficiaries. Sepsis was identified using inpatient Medicare claims. Associations with sepsis were estimated using logistic regression.
RESULTS: After correction for multiple comparisons, sepsis was significantly associated with increased risk for cancers of the colon (adjusted odds ratio [aOR] = 1.12), rectum (1.13), liver (1.47), lung (1.17), and cervix (1.52), as well as acute myeloid leukemia (AML, 1.19), chronic myeloid leukemia (1.54), and myelodysplastic syndrome (1.30). Inverse associations were observed for cancers of the breast (aOR = 0.86), prostate (0.75), kidney (0.90), and thyroid (0.68) and for melanoma (0.83), diffuse large B-cell lymphoma (0.89), and follicular lymphoma (0.65). Sepsis was significantly associated with the following 9 types of cancer in the period >5 years following sepsis diagnosis: thyroid, prostate, colon, rectum, lung, and liver and follicular lymphoma, melanoma, and AML.
CONCLUSIONS: Sepsis is associated with increased or decreased risks for a small group of cancers. Factors that may explain these associations include etiologic effects. Other associations may reflect the presence of precursor conditions or patterns in ascertainment of cancer and screening. Published by Oxford University Press for the Infectious Diseases Society of America 2018.

Entities:  

Keywords:  Surveillance Epidemiology End Results (SEER)-Medicare; cancers; elderly; sepsis

Mesh:

Year:  2019        PMID: 29982318      PMCID: PMC6376110          DOI: 10.1093/cid/ciy530

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Chlamydia pneumoniae infection and risk for lung cancer.

Authors:  Anil K Chaturvedi; Charlotte A Gaydos; Patricia Agreda; Jeffrey P Holden; Nilanjan Chatterjee; James J Goedert; Neil E Caporaso; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.

Authors:  J V Selby; G D Friedman; B H Fireman
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

3.  Immunosuppression in patients who die of sepsis and multiple organ failure.

Authors:  Jonathan S Boomer; Kathleen To; Kathy C Chang; Osamu Takasu; Dale F Osborne; Andrew H Walton; Traci L Bricker; Stephen D Jarman; Daniel Kreisel; Alexander S Krupnick; Anil Srivastava; Paul E Swanson; Jonathan M Green; Richard S Hotchkiss
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

4.  Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia.

Authors:  Julie A Ross; Cindy K Blair; James R Cerhan; John T Soler; Betsy A Hirsch; Michelle A Roesler; Rodney R Higgins; Phuong L Nguyen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-29       Impact factor: 4.254

5.  Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Malin Hultcrantz; Åsa R Derolf; Ola Landgren; Lynn R Goldin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

Review 6.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

7.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

Review 8.  Epidemiology of severe sepsis.

Authors:  Florian B Mayr; Sachin Yende; Derek C Angus
Journal:  Virulence       Date:  2013-12-11       Impact factor: 5.882

9.  Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.

Authors:  Raúl U Hernández-Ramírez; Meredith S Shiels; Robert Dubrow; Eric A Engels
Journal:  Lancet HIV       Date:  2017-08-10       Impact factor: 12.767

10.  Associations of antibiotic use with risk of primary liver cancer in the Clinical Practice Research Datalink.

Authors:  Baiyu Yang; Katrina Wilcox Hagberg; Jie Chen; Vikrant V Sahasrabuddhe; Barry I Graubard; Susan Jick; Katherine A McGlynn
Journal:  Br J Cancer       Date:  2016-05-24       Impact factor: 7.640

View more
  11 in total

1.  Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity.

Authors:  Clara Vigneron; Adrien Mirouse; Hamid Merdji; Christophe Rousseau; Clément Cousin; Fanny Alby-Laurent; Jean-Paul Mira; Jean-Daniel Chiche; Jean-François Llitjos; Frédéric Pène
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

2.  RBM4 modulates the proliferation and expression of inflammatory factors via the alternative splicing of regulatory factors in HeLa cells.

Authors:  Wei-Yang Wang; Weili Quan; Fan Yang; Ya-Xun Wei; Jia-Jun Chen; Han Yu; Jie Xie; Yi Zhang; Zhan-Fei Li
Journal:  Mol Genet Genomics       Date:  2019-09-05       Impact factor: 3.291

3.  Epidemiology and Outcomes of Cancer-Related Versus Non-Cancer-Related Sepsis Hospitalizations.

Authors:  Matthew K Hensley; John P Donnelly; Erin F Carlton; Hallie C Prescott
Journal:  Crit Care Med       Date:  2019-10       Impact factor: 7.598

4.  Harnessing the Versatility of Invariant NKT Cells in a Stepwise Approach to Sepsis Immunotherapy.

Authors:  Joshua Choi; Tina S Mele; Steven A Porcelli; Paul B Savage; S M Mansour Haeryfar
Journal:  J Immunol       Date:  2020-12-11       Impact factor: 5.422

5.  Causes of death following small cell lung cancer diagnosis: a population-based analysis.

Authors:  Xue-Qin Wu; Jing-Yi Li; Wen-Jing Du
Journal:  BMC Pulm Med       Date:  2022-07-04       Impact factor: 3.320

6.  Association of Sepsis Mortality with Specific Cancer Sites and Treatment Type: The Multiethnic Cohort Study.

Authors:  Yurii B Shvetsov; Mari H Ogino; Natalija Glibetic; Chloe B Asato; Lynne R Wilkens; Loïc Le Marchand; Michelle L Matter
Journal:  J Pers Med       Date:  2021-02-19

Review 7.  Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.

Authors:  Carlota Gudiol; Adaia Albasanz-Puig; Guillermo Cuervo; Jordi Carratalà
Journal:  Front Med (Lausanne)       Date:  2021-03-31

8.  The Use of qSOFA, SOFA, and Ramathibodi Early Warning Score (REWS) to Predict Severe Complications in Hematologic Malignancy Patients.

Authors:  Pungkava Sricharoen; Chaithawat Chueluecha; Chaiyaporn Yuksen; Chetsadakon Jenpanitpong
Journal:  Open Access Emerg Med       Date:  2022-02-05

9.  Sepsis-associated pathways segregate cancer groups.

Authors:  Himanshu Tripathi; Samanwoy Mukhopadhyay; Saroj Kant Mohapatra
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

10.  Increased risk of incident primary cancer after Staphylococcus aureus bacteremia: A matched cohort study.

Authors:  Nanja Gotland; M L Uhre; H Sandholdt; N Mejer; L F Lundbo; A Petersen; A R Larsen; T Benfield
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.